Capricor End Period Cash Flow from 2010 to 2025

CAPR Stock  USD 13.18  0.30  2.23%   
Capricor Therapeutics End Period Cash Flow yearly trend continues to be relatively stable with very little volatility. End Period Cash Flow is likely to grow to about 17.7 M this year. During the period from 2010 to 2025, Capricor Therapeutics End Period Cash Flow destribution of quarterly values had r-value of  0.66 from its regression line and median of  6,882,137. View All Fundamentals
 
End Period Cash Flow  
First Reported
2001-03-31
Previous Quarter
10.7 M
Current Value
68.4 M
Quarterly Volatility
12.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Capricor Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Capricor Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 2 M or Other Operating Expenses of 68.1 M, as well as many indicators such as Price To Sales Ratio of 20.73, Dividend Yield of 0.0 or PTB Ratio of 7.48. Capricor financial statements analysis is a perfect complement when working with Capricor Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Capricor Therapeutics Correlation against competitors.
To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Latest Capricor Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Capricor Therapeutics over the last few years. It is Capricor Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Capricor Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Capricor End Period Cash Flow Regression Statistics

Arithmetic Mean10,090,058
Coefficient Of Variation107.26
Mean Deviation8,304,855
Median6,882,137
Standard Deviation10,822,248
Sample Variance117.1T
Range34.9M
R-Value0.66
Mean Square Error70T
R-Squared0.44
Significance0
Slope1,511,081
Total Sum of Squares1756.8T

Capricor End Period Cash Flow History

202517.7 M
202416.9 M
202314.7 M
20229.6 M
202134.9 M
202032.7 M
20193.9 M

About Capricor Therapeutics Financial Statements

Capricor Therapeutics shareholders use historical fundamental indicators, such as End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Capricor Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Capricor Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Capricor Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow16.9 M17.7 M

Pair Trading with Capricor Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.